Altimmune, Inc. (ALT) Free cash flow 2016–2025
Altimmune, Inc. (ALT) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$67.5MFY2025 · since FY2016: -$6.5M → -$67.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$67.5M | — |
| FY2023 | -$75.9M | -21.0% |
| FY2022 | -$62.7M | +30.6% |
| FY2021 | -$90.4M | -161.8% |
| FY2020 | -$34.5M | -259.4% |
| FY2019 | -$9.6M | +7.3% |
| FY2018 | -$10.4M | +49.0% |
| FY2017 | -$20.3M | -213.8% |
| FY2016 | -$6.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice